414909-98-1

Usage

InChI:InChI=1/C20H18FNO3/c1-14-11-16(21)7-8-18(14)19-12-17(23)9-10-22(19)20(24)25-13-15-5-3-2-4-6-15/h2-11,19H,12-13H2,1H3

Upstream product

• 452-63-1 2-Bromo-5-fluorotoluene 
• 620-08-6 4-methoxypyridine 
• 501-53-1 benzyl chloroformate 
• 7439-95-4 magnesium 

Downstream Products

• 414910-14-8 (2R)-N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-oxo-1-piperidinecarboxamide 
• 579475-69-7 2-(4-fluoro-2-methylphenyl)-4-piperidinone camphor-10-sulfonate 
• 758683-83-9 C₂₈H₃₂F₇N₃O 
• 732982-99-9 C₂₈H₃₂F₇N₃O 
• 692257-60-6 C₂₇H₃₀F₇N₃O 
• 740081-53-2 C₂₇H₃₀F₇N₃O 
• 1265855-31-9 C₂₇H₃₀F₇N₃O 
• 1265855-27-3 C₂₇H₃₀F₇N₃O 
• 1265854-91-8 C₂₆H₂₈F₇N₃O 
• 578710-96-0 C₂₆H₃₀F₇N₃O 
• 578710-94-8 C₂₆H₃₀F₇N₃O 
• 578711-00-9 C₂₅H₂₈F₇N₃O 
• 578710-98-2 C₂₅H₂₈F₇N₃O 
• 414910-03-5 (2R)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4-oxo-1-piperidinecarboxamide 

Relevant academic research and scientific papers

Discovery and biological characterization of (2 R,4 S)-1′-Acetyl- N -{(1 R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)- N -methyl-4,4′-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) recepto

A large body of compelling preclinical evidence supports the clinical use of neurokinin (NK) receptor antagonists in a plethora of CNS and non-CNS therapeutic areas. The significant investment made in this area over the past 2 decades culminated with the

Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss

The present invention relates to methods for treating a subject suffering from tinnitus, hearing loss, or tinnitus and hearing loss comprising administering to the subject an effective amount of an NK1 receptor antagonist alone, or in combination with an

PIPERIDINE COMPOUND AND METHOD FOR PRODUCING SAME

The present invention relates to a novel piperidine compound represented by the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally

NK1 ANTAGONIST

The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-meditated conditions.Formula (I)

Chemical compounds

Formula (1) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluorometyl group; R5 represents hydrogen, a C1-4 alkyl group or C(0)R6; R6? represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.

NOVEL PIPERIDINE COMPOUND

The present invention provides a novel piperidine compound of the formula [I]: wherein Ring A represents an optionally substituted benzene ring, Ring B represents an optionally substituted benzene ring, R1 represents an optionally substituted alkyl group, an optionally substituted hydroxyl group, etc., or a group of the formula: (a) wherein R11 and R12 are the same or different, and each represents hydrogen atom, a substituted carbonyl group, a substituted sulfonyl group, an optionally substituted alkyl group, etc., R2 represents hydrogen atom, etc., Z represents oxygen atom or a group represented by -N(R3)-, R3 represents hydrogen atom or an alkyl group, etc., R4 represents hydrogen atom or an alkyl group, etc.,or a pharmaceutically acceptable salt thereof.